FACTORS ASSOCIATED WITH A LACK OF VIRAL SUPPRESSION IN CHRONIC HBV ( CHB) PATIENTS AFTER 8 YEARS OF TREATMENT WITH TENOFOVIR ALAFENAMIDE ( TAF) OR TENOFOVIR DISOPROXIL FUMARATE ( TDF) FOLLOWED BY TAF TREATMENT
Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, United States Of America, 10 - 14 November 2023, (Summary Text)
